Version July 2025
| HBsAg | HBeAg | IgM anti-HBc | Total anti-HBc* | Anti-HBs | Anti-HBe | HBV DNA | ALT¶ | Interpretation |
| Acute HBV infection | ||||||||
| + | + | + | ± | +++ | Elevated | Early phase | ||
| + | ± | + | Elevated | Window phase | ||||
| + | + | + | ± | Normal | Recovery phase | |||
| Chronic HBV infection (HBsAg-positive for >6 months) | ||||||||
| + | + | + | – | – | +++ (typically >1 million international units/mL) | Normal or mildly elevated | Immune-tolerant phaseΔ | |
| + | + | + | – | – | +++ (>20,000 international units/mL) | Persistently elevated | Immune-active, HBeAg-positive◊ | |
| + | – | + | – | + | ++ (>2000 international units/mL) | Elevated | Immune-active, HBeAg-negative◊ | |
| + | – | + | + | – to ++ (≤2000 international units/mL) | Normal or mildly elevated | Inactive chronic HBV§ | ||
| – | – | ± (generally +) | ± | ± | Detected in liver, generally not detected or detected at low levels in serum | Normal | Occult HBV | |
ALT: alanine aminotransferase; anti-HBc: antibody to hepatitis B core antigen; anti-HBe: antibody to hepatitis B e antigen; anti-HBs: antibody to hepatitis B surface antigen; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus.
* This test is typically ordered as total anti-HBc, which includes IgM and IgG.
¶ The upper limits of normal for ALT in healthy adults are reported to be 29 to 33 units/L for males and 19 to 25 units/L for females. For healthy children after infancy, the upper limits of normal are 25 to 38 units/L and 22 to 31 units/L for boys and girls, respectively.
Δ For patients with immune-tolerant chronic hepatitis B, liver biopsy or noninvasive tests show no fibrosis and minimal inflammation. This is the initial phase seen in patients with perinatally acquired HBV infection.
◊ For patients with immune active chronic hepatitis B, liver biopsy or noninvasive tests usually show chronic hepatitis with necroinflammation with or without fibrosis. For patients who are HBeAg positive, immune-active chronic hepatitis B (also known as the clearance phase) can last for 10 to 20 years and may be associated with the loss of HBeAg. For patients who are HBeAg negative, immune-active chronic hepatitis B is often associated with precore or core promoter HBV variants and is also referred to as HBeAg-negative chronic hepatitis B or HBeAg-negative replicative phase.
§ Patients with inactive chronic hepatitis B are HBeAg negative. In such patients, liver biopsy generally shows the absence of significant necroinflammation, but biopsy or noninvasive testing show variable levels of fibrosis. This stage has also been referred to as the carrier phase.